Niquitin Minilozenge (Nicotine)

Nicotine, the active ingredient in Niquitin Minilozenge, is a nicotinic receptor agonist presented as an oromucosal lozenge for smoking cessation. It is indicated for adult smokers seeking to reduce withdrawal symptoms and cravings during a quit attempt.

GNH USA supplies Niquitin Minilozenge as a licensed, GDP‑compliant product sourced from the EU market, providing reliable access to hospitals, pharmacies and clinics worldwide, and adhering to stringent quality and regulatory standards for international distribution. The supply chain is supported by robust logistics and compliance frameworks.

Niquitin Minilozenge, a nicotinic receptor agonist, is used in smoking cessation therapy. - Aid to quit smoking: helps adult smokers reduce cravings and withdrawal symptoms during cessation attempts. - Relapse prevention: supports individuals who have recently stopped smoking to maintain abstinence. - Adjunct to behavioral counseling: used together with counseling programs to improve quit rates. - Nicotine dependence management: assists in managing physiological dependence on nicotine.

Common Side Effects: - Mouth irritation: mild soreness or tingling in the oral cavity. - Nausea: feeling of queasiness after lozenge use. - Hiccups: transient diaphragmatic spasms. - Increased salivation: excess saliva production. - Dyspepsia: mild stomach discomfort.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Chest pain: possible cardiac symptoms requiring evaluation. - Persistent vomiting: may lead to dehydration.

Precautions for Niquitin Minilozenge include: - Assess nicotine dependence: evaluate level before initiating therapy. - Avoid use in non‑smokers: not indicated for nicotine‑naïve individuals. - Monitor cardiovascular status: use cautiously in patients with recent heart disease. - Consider pregnancy and lactation: safety not established; discuss with healthcare provider. - Do not exceed recommended lozenge frequency: follow prescriber guidance to avoid nicotine overdose. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Niquitin Minilozenge may interact with other substances. Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use may increase risk of hypertensive crisis. - Other nicotine replacement products: combined use can cause nicotine toxicity. - CYP2A6 inhibitors: may elevate nicotine plasma levels.

Moderate Interactions (Monitor Closely): - Caffeine: nicotine may enhance stimulant effects, monitor for jitteriness. - Alcohol: combined use may increase cardiovascular strain.